Approval to Covaxin premature, could be dangerous, says Shashi Tharoor

Senior Congress leader Shashi Tharoor on Sunday said that the emergency approval to Covid-19 vaccine--Covaxin is premature and could be dangerous as it is still under phase 3 trial

Shashi Tharoor addressing audience at Jaipur Literary Fest
Shashi Tharoor
ANI General News
2 min read Last Updated : Jan 03 2021 | 2:39 PM IST

Senior Congress leader Shashi Tharoor on Sunday said that the emergency approval to COVID-19 vaccine--Covaxin is premature and could be dangerous as it is still under phase 3 trial. He urged Union Health Minister Dr Harsh Vardhan to wait till full trials of the vaccine are completed.

Taking to Twitter, Member of Parliament from Kerala's Thiruvananthapuram said, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous."

He further urged Union Health Minister Dr Harsh Vardhan to avoid Covaxin till full trials are over.

"Union Health Minister Dr Harsh Vardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," he added in the tweet.

Earlier today, COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in an emergency situation, said DCGI.

"After adequate examination, Central Drugs Standard Control Organisation(CDSCO) has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial," said VG Somani, DCGI, during a media briefing today.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Shashi TharoorCoronavirus VaccineHealth MinistryHealth crisisIndian healthcare system

First Published: Jan 03 2021 | 2:35 PM IST

Next Story